Media Room



Latest News Releases
Jul 18, 2017

Nektar Therapeutics (NASDAQ: NKTR) announced positive topline results from an oral Human Abuse Potential (HAP) study of NKTR-181, a first-in-class opioid analgesic. NKTR-181 is a new chemical...

Jul 10, 2017

Nektar Therapeutics (NASDAQ: NKTR) today announced positive preclinical results for NKTR-358, a first-in-class resolution therapeutic for autoimmune disease. The new preclinical data demonstrate...

Jun 6, 2017

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 Global Healthcare Conference in New York City on Wednesday, June...

More »

Multimedia Libraries
Media Contacts
Dan Budwick
Pure Communications, Inc.

More »

Follow Us on LinkedIn
Follow Us on Twitter

print email
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide